Dual improvement of alopecia areata and immune thrombocytopenia with baricitinib: a case report
Authors:
Open Access
- 22 January 2025
- journal article
- case report
- Published by Oxford University Press (OUP) in Skin Health and Disease
- Vol. 5 (1) , 66-69
Abstract
The oral Janus kinase (JAK) inhibitor baricitinib is approved by the U.S. Food and Drug Administration for the treatment of alopecia areata (AA). We report a case of dual improvement of AA and immune thrombocytopenia (ITP) with oral baricitinib monotherapy, which may suggest linked autoimmune pathophysiology. In phase III clinical trials of baricitinib for AA, reports of rare adverse haematological events include neutropenia and anaemia. While a history of haematological comorbidities may raise concern for many clinicians when considering treatment with a JAK inhibitor, this clinical vignette suggests that baricitinib may be considered and safely administered in those with concomitant AA and ITP. A 56-year-old man with a history of AA, ITP and vitiligo presented to the clinic for relapse of his steroid-resistant hair loss which had previously been treated with tofacitinib. In consultation with the patient’s haematologist, baricitinib 2 mg daily was started with close platelet monitoring then doubled to 4 mg after platelets showed improvement at the 6-month follow-up. Fourteen months after initiating baricitinib, improvement in white and dark hair regrowth was observed, and platelets remained normal. Thus, baricitinib may be considered for the dual treatment of AA and ITP with regular platelet monitoring and co-management with haematology colleagues.Keywords
This publication has 12 references indexed in Scilit:
- Safety and efficacy of baricitinib in steroid‐resistant or relapsed immune thrombocytopenia: An open‐label pilot studyAmerican Journal of Hematology, 2024
- A case of alopecia areata multiplex accompanied by chronic idiopathic thrombocytopenic purpuraThe Journal of Dermatology, 2024
- Two Phase 3 Trials of Baricitinib for Alopecia AreataNew England Journal of Medicine, 2022
- Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case reportWorld Journal of Clinical Cases, 2020
- Immune ThrombocytopeniaNew England Journal of Medicine, 2019
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor BaricitinibEBioMedicine, 2015
- Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesisBlood, 2014
- Immune thrombocytopenia and alopecia areata: Spontaneous occurrence and resolution in the same patientPediatric Blood & Cancer, 2014
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibitionNature Medicine, 2014
- Simultaneous Onset of Alopecia Areata and Idiopathic Thrombocytopenic Purpura: A Potential Association?Pediatric Dermatology, 1999